Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021
Organon (NYSE: OGN) is set to release its Q2 2021 financial results on August 12, 2021, prior to a conference call at 8:30 a.m. ET. Interested parties can access the live call via webcast. Following the call, a replay will be available on the company’s website. Organon focuses on women's health with over 60 products, including a strong reproductive health portfolio and expanding biosimilars business, supported by strong cash flows. The company aims for growth through acquisitions and collaborations in international markets.
- Strong product portfolio with over 60 medicines.
- Focus on women's health offers substantial market opportunity.
- Acquisition of Alydia Health enhances business development in postpartum hemorrhage.
- Stable cash flows support future growth investments.
- None.
Organon (NYSE: OGN) will release its second quarter 2021 financial results on August 12, 2021, prior to the company’s webcast and conference call scheduled for 8:30 a.m. ET.
Interested parties may access the live call via webcast on the Organon website at https://www.organon.com/investor-relations/. A replay of the webcast will be available approximately two hours after the conclusion of the live event on the company’s website.
Institutional investors and analysts interested in participating in the call must register in advance by clicking on this link: http://www.directeventreg.com/registration/event/9577397. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including dial-in information and a unique passcode and registrant ID. Pre-registration will allow participants to bypass an operator and be placed directly into the call.
About Organon
Organon (NYSE: OGN) is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, to focus on improving the health of women throughout their lives. Here for her health, the company has a portfolio of more than 60 medicines and products across a range of therapeutic areas. Led by the reproductive health portfolio coupled with an expanding biosimilars business and stable franchise of established medicines, Organon’s products produce strong cash flows that will support investments in future growth opportunities in women’s health, including business development, including business development like recently acquired Alydia Health, a medical device company focused on postpartum hemorrhage. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.
Organon has a global footprint with significant scale and geographic reach, world-class commercial capabilities, and approximately 9,000 employees with headquarters located in Jersey City, New Jersey.
For more information, visit http://www.organon.com and connect with us on LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210722005370/en/
FAQ
When will Organon release its Q2 2021 earnings?
What time is the Organon conference call for Q2 2021 results?
How can I access Organon's Q2 2021 earnings call?
What is the focus of Organon's product portfolio?
What is the significance of Organon's acquisition of Alydia Health?
